Catalyst will use Biocept's liquid biopsy platform to screen for cancer in patients in a clinical study of its rare disease drug Firdapse.
The company said it accessioned 1,175 total samples during the quarter, up from 663 total samples in Q4 2015.
Ahead of a longer-term goal to develop IVD kits, the company has a plan this year to allow early-access customers to take on one aspect of testing in their own labs.
The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.
Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.
The company said in a filing with the US Securities and Exchange Commission that it failed to maintain compliance with the Nasdaq's minimum closing bid price requirement.
The maker of cancer biomarker assays reported record revenues of more than $1 million in the quarter compared to $164,858 in the prior-year period.
The company sold 9.1 million shares of its common stock and warrants to purchase up to 9.1 million more shares at a combined offering price of $1.10 per share.
The company is offering 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million additional shares.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.